Clinical trial
A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
NCT03065959 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- June 28, 2017
- Completion date
- October 10, 2018
- Enrollment
- 42 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.